Literature DB >> 34916189

[Regulatory mechanism of interferon regulatory factor 1 by α-synuclein in mouse Parkinson's disease model].

F Mu1, X Chen1, X DU1, Q Jiao1, M Bi1, H Jiang1.   

Abstract

OBJECTIVE: To investigate the molecular mechanism by which α-synuclein (α-Syn) regulates interferon regulatory factor 1 (IRF-1) expression.
METHODS: SH-SY5Y cells overexpressing α-Syn and transgenic mouse model carrying human α-Syn gene with A53T mutation (3 and 6 months old) were examined for IRF-1 mRNA and protein expressions using real-time PCR and Western blotting, respectively. The subcellular localization of IRF-1 was determined with immunofluorescence staining and cytoplasmic/nuclear protein isolation. The optimal concentrations of the proteasome inhibitor MG132 (0.01-2.0 μmol/L) and lysosomal inhibitor chloroquine (5-200 μmol/L) for treatment of SH-SY5Y cells for 24 h were determined by examining the cell viability. SH-SY5Y cells were treated with 0.2 μmol/L MG132 and 30 μmol/L chloroquine for 24 h (the maximum dose that did not cause cell damage), and the changes of IRF-1 protein expressions was analyzed. The effects of α-Syn on MDM2 protein expression and IRF-1 ubiquitylation were analyzed using Western blotting and ubiquitylation assay.
RESULTS: α-Syn overexpression did not affect the mRNA level of IRF-1 but significantly increased its protein level (P < 0.01). In α-Synoverexpressing SH-SY5Y cells, IRF-1 translocation was observed from the cytoplasm to the nucleus (P < 0.001). Treatment of the cells with 0.2 μmol/L MG132 significantly aggravated α-Syn-induced increase of IRF-1 protein expression (P < 0.01) while 30 μmol/L chloroquine produced no significant changes in IRF-1 level. α-Syn overexpression caused an obvious decrease of MDM2 protein level and further inhibited the ubiquitylation of IRF-1 (P < 0.01).
CONCLUSION: α-Syn blocks MDM2-mediated ubiquitylation of IRF-1 through ubiquitin proteasome pathway, thereby enhancing IRF-1 protein expression.

Entities:  

Keywords:  Parkinson's disease; interferon regulatory factor 1; neuroimmune; α-synuclein

Mesh:

Substances:

Year:  2021        PMID: 34916189      PMCID: PMC8685704          DOI: 10.12122/j.issn.1673-4254.2021.11.07

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  45 in total

1.  Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration.

Authors:  Liya Qin; Xuefei Wu; Michelle L Block; Yuxin Liu; George R Breese; Jau-Shyong Hong; Darin J Knapp; Fulton T Crews
Journal:  Glia       Date:  2007-04-01       Impact factor: 7.452

Review 2.  α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities.

Authors:  Parvez Alam; Luc Bousset; Ronald Melki; Daniel E Otzen
Journal:  J Neurochem       Date:  2019-08-02       Impact factor: 5.372

3.  Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease.

Authors:  Honglei Chen; Shumin M Zhang; Miguel A Hernán; Michael A Schwarzschild; Walter C Willett; Graham A Colditz; Frank E Speizer; Alberto Ascherio
Journal:  Arch Neurol       Date:  2003-08

4.  T cells from patients with Parkinson's disease recognize α-synuclein peptides.

Authors:  David Sulzer; Roy N Alcalay; Francesca Garretti; Lucien Cote; Ellen Kanter; Julian Agin-Liebes; Christopher Liong; Curtis McMurtrey; William H Hildebrand; Xiaobo Mao; Valina L Dawson; Ted M Dawson; Carla Oseroff; John Pham; John Sidney; Myles B Dillon; Chelsea Carpenter; Daniela Weiskopf; Elizabeth Phillips; Simon Mallal; Bjoern Peters; April Frazier; Cecilia S Lindestam Arlehamn; Alessandro Sette
Journal:  Nature       Date:  2017-06-21       Impact factor: 49.962

5.  Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype.

Authors:  Degao Chen; Jing Xie; Roland Fiskesund; Wenqian Dong; Xiaoyu Liang; Jiadi Lv; Xun Jin; Jinyan Liu; Siqi Mo; Tianzhen Zhang; Feiran Cheng; Yabo Zhou; Huafeng Zhang; Ke Tang; Jingwei Ma; Yuying Liu; Bo Huang
Journal:  Nat Commun       Date:  2018-02-28       Impact factor: 14.919

Review 6.  Inflammasomes in neuroinflammatory and neurodegenerative diseases.

Authors:  Sofie Voet; Sahana Srinivasan; Mohamed Lamkanfi; Geert van Loo
Journal:  EMBO Mol Med       Date:  2019-06       Impact factor: 12.137

Review 7.  Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses.

Authors:  Hui Feng; Yi-Bing Zhang; Jian-Fang Gui; Stanley M Lemon; Daisuke Yamane
Journal:  PLoS Pathog       Date:  2021-01-21       Impact factor: 6.823

Review 8.  Advancing targeted protein degradation for cancer therapy.

Authors:  Brandon Dale; Meng Cheng; Kwang-Su Park; H Ümit Kaniskan; Yue Xiong; Jian Jin
Journal:  Nat Rev Cancer       Date:  2021-06-15       Impact factor: 60.716

Review 9.  Ubiquitin modifications.

Authors:  Kirby N Swatek; David Komander
Journal:  Cell Res       Date:  2016-03-25       Impact factor: 25.617

Review 10.  Innate Immunity and Neurodegeneration.

Authors:  Larisa I Labzin; Michael T Heneka; Eicke Latz
Journal:  Annu Rev Med       Date:  2017-11-06       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.